Progression of carotid near-occlusion to complete occlusion: related factors and clinical implications.


Journal

Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079

Informations de publication

Date de publication:
Dec 2020
Historique:
received: 17 11 2019
revised: 03 03 2020
accepted: 11 03 2020
pubmed: 12 4 2020
medline: 9 2 2021
entrez: 12 4 2020
Statut: ppublish

Résumé

The clinical consequences and factors related to the progression from a carotid near-occlusion (CNO) to a complete occlusion are not well established. Our aim is to describe the rate, predictive factors and clinical implications of the progression to complete carotid occlusion (PCCO) in a population of patients with symptomatic CNO. We conducted a multicenter, nationwide, prospective study from January 2010 to May 2016. Patients with angiography-confirmed CNO were included. We collected information on demographic data, clinical manifestations, radiological and hemodynamic findings, and treatment modalities. A 24 month carotid-imaging follow-up of the CNO was performed. 141 patients were included in the study, and carotid-imaging follow-up was performed in 122 patients. PCCO occurred in 40 patients (32.8%), and was more frequent in medically-treated patients (34 out of 61; 55.7%) compared with patients treated with revascularization (6 out of 61; 9.8%) (p<0.001). 7 of the 40 patients with PCCO (17.5%) suffered ipsilateral symptoms. Factors independently related with PCCO in the multivariate analysis were: age ≥75 years (OR 2.93, 95% CI 1.05 to 8.13), revascularization (OR 0.07, 95% CI 0.02 to 0.20), and collateral circulation through the ipsilateral ophthalmic artery (OR 3.25, 95% CI 1.01 to 10.48). PCCO occurred within 24 months in more than half of the patients under medical treatment. Most episodes of PCCO were not associated with ipsilateral symptoms. Revascularization reduces the risk of PCCO.

Sections du résumé

BACKGROUND BACKGROUND
The clinical consequences and factors related to the progression from a carotid near-occlusion (CNO) to a complete occlusion are not well established. Our aim is to describe the rate, predictive factors and clinical implications of the progression to complete carotid occlusion (PCCO) in a population of patients with symptomatic CNO.
METHODS METHODS
We conducted a multicenter, nationwide, prospective study from January 2010 to May 2016. Patients with angiography-confirmed CNO were included. We collected information on demographic data, clinical manifestations, radiological and hemodynamic findings, and treatment modalities. A 24 month carotid-imaging follow-up of the CNO was performed.
RESULTS RESULTS
141 patients were included in the study, and carotid-imaging follow-up was performed in 122 patients. PCCO occurred in 40 patients (32.8%), and was more frequent in medically-treated patients (34 out of 61; 55.7%) compared with patients treated with revascularization (6 out of 61; 9.8%) (p<0.001). 7 of the 40 patients with PCCO (17.5%) suffered ipsilateral symptoms. Factors independently related with PCCO in the multivariate analysis were: age ≥75 years (OR 2.93, 95% CI 1.05 to 8.13), revascularization (OR 0.07, 95% CI 0.02 to 0.20), and collateral circulation through the ipsilateral ophthalmic artery (OR 3.25, 95% CI 1.01 to 10.48).
CONCLUSIONS CONCLUSIONS
PCCO occurred within 24 months in more than half of the patients under medical treatment. Most episodes of PCCO were not associated with ipsilateral symptoms. Revascularization reduces the risk of PCCO.

Identifiants

pubmed: 32277038
pii: neurintsurg-2019-015638
doi: 10.1136/neurintsurg-2019-015638
doi:

Types de publication

Journal Article Multicenter Study Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

1180-1185

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Andrés García-Pastor (A)

Hospital General Universitario Gregorio Marañón, Madrid, Spain angarpas@yahoo.es.

Antonio Gil-Núñez (A)

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

José María Ramírez-Moreno (JM)

Hospital Universitario Infanta Cristina, Badajoz, Spain.

Noelia González-Nafría (N)

Complejo Asistencial Universitario de León, León, Spain.

Javier Tejada (J)

Complejo Asistencial Universitario de León, León, Spain.

Francisco Moniche (F)

Hospital Universitario Virgen del Rocio, Seville, Spain.

Juan Carlos Portilla-Cuenca (JC)

Hospital San Pedro de Alcántara, Caceres, Spain.

Patricia Martínez-Sánchez (P)

Hospital Universitario La Paz, Madrid, Spain.

Blanca Fuentes (B)

Hospital Universitario La Paz, Madrid, Spain.

Miguel Ángel Gamero-García (MÁ)

Hospital Universitario Virgen Macarena, Sevilla, Spain.

María Alonso de Leciñana (M)

Hospital Universitario Ramón y Cajal, Madrid, Spain.

Jaime Masjuan (J)

Hospital Universitario Ramón y Cajal, Madrid, Spain.

David Cánovas (D)

Hospital Parc Taulí, Sabadell, Spain.

Yolanda Aladro (Y)

Hospital Universitario de Getafe, Getafe, Spain.

Vera Parkhutik (V)

Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Aida Lago (A)

Hospital Universitari i Politècnic La Fe, Valencia, Spain.

Ana María De Arce (AM)

Hospital Universitario de Donostia, San Sebastian, Spain.

María Usero-Ruiz (M)

Hospital Clinico Universitario de Valladolid, Valladolid, Spain.

Raquel Delgado-Mederos (R)

Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.

Ana Pampliega (A)

Hospital General Universitari d'Alacant, Alicante, Spain.

Álvaro Ximénez-Carrillo (Á)

Hospital Universitario de La Princesa, Madrid, Spain.

Mónica Bártulos-Iglesias (M)

Complejo Asistencial Univeristario de Burgos, Burgos, Spain.

Enrique Castro-Reyes (E)

Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH